Drug Profile
MEDI 7814
Alternative Names: MEDI7814Latest Information Update: 09 Aug 2021
Price :
$50
*
At a glance
- Originator MedImmune
- Class Monoclonal antibodies
- Mechanism of Action Complement C5a inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Chronic obstructive pulmonary disease
Most Recent Events
- 21 Mar 2013 Discontinued - Phase-I for Chronic obstructive pulmonary disease (in volunteers) in USA (IV)
- 09 Jul 2012 MedImmune completes enrolment in its phase I trial in Healthy volunteers in USA (NCT01544361)
- 29 Feb 2012 Phase-I clinical trials in Chronic obstructive pulmonary disease (in healthy volunteers) in USA (IV)